Flavopiridol HCl
CDK inhibitor / Cyclin-dependent kinase (CDK) inhibitor that causes cell cycle arrest at G1 and G2 phase1. Potentiates (100-200 nM) PMA-induced apoptosis in HL-60 and U937 cells2. Potentiates the effects of topoisomerase I inhibitors by suppressing Rad51 expression in a p53-dependent manner. Displays potent antiviral activity against HIV-1 and HSV-1 in vitro4.
Biochemicals & reagents
131740-09-5
L 86-8275; Alvocidib; NSC-649890
1) Kaur et al. (1992), Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275; J. Natl. Cancer Inst., 84 1736 2) Cartee et al. (2002), Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways; Mol. Pharmacol., 61 1313 3) Ambrosini et al. (2008), The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner; Cancer Res. 68 2312 4) Schang et al. (2004), Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication; Biochim. Biophys. Acta, 1697 197
-20°C
TARGET: Kinase -- PATHWAY: Cell cycle; Apoptosis inducer; DNA damage; p53 -- RESEARCH AREA: Cell death -- DISEASE AREA: Infectious disease